The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
The FDA issued a second complete response letter for deramiocel in Duchenne muscular dystrophy, citing insufficient evidence of effectiveness from the phase 3 HOPE-3 trial.
Chris Favilla, MD, stroke neurologist at the University of Pennsylvania, discusses findings that cerebral venous sinus stenting improves arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH) and what they mean for understanding the disease.
5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.
William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.